💡 Did you know?
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
History
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
Neuland Laboratories Ltd. is a global provider of active pharmaceutical ingredients (APIs) contract development and manufacturing organization (CDMO) services. It is focused on manufacture and sale of active pharmaceutical ingredients and allied services. It supports…
Weekly engine runs — movement reflects the numbers, not analyst opinion.
A high-quality, fast-growing business, priced for perfection.
Neuland Lab is scored on the pharma / healthcare framework. It keeps a healthy 17.7% of every rupee of sales as net profit. Cash broadly tracks reported profit (CFO/PAT 0.95×). Free cash flow is worth about -0.3% of its market value.
Over the last 3 years revenue compounded at 20%/yr and profit at 31%/yr. Book value itself has compounded 24%/yr — the hallmark of a genuine compounder. Return on equity is an elite 22.3%. In the latest quarter profit fell 31% versus the prior quarter.
At 69× earnings, the stock sits at the 83rd percentile of its own 3.6-year range — the expensive end of where it has historically traded. Today's price already implies ~23%/yr earnings growth sustained for a decade — a demanding bar. The books come through clean — a forensic grade of A, and Altman puts distress risk in the safe zone.
A plain-English restatement of the figures on this page — rules-based, for education and research context, not investment advice or a recommendation.
| Ratio | Company | Sector | Read |
|---|---|---|---|
| P/E | 55.84 | — | — |
| P/B | 12.46 | 4.1 | worse |
| EV/EBITDA | 34.09 | 19.33 | worse |
| ROE | 22.3 | — | — |
| ROCE | 26.86 | 14.41 | better |
| ROA | 14.94 | — | — |
| Quick Ratio | 1.37 | 4.8 | worse |
| Peer | P/E | P/B | ROE |
|---|---|---|---|
| Sun Pharmaceutical Industries | 40.6 | 5.0 | 13.8% |
| Divis Laboratories | 93.5 | 16.3 | 15.3% |
| Torrent Pharmaceuticals | 85.9 | 9.8 | 11.4% |
20% CAGR over 3 years — steady double-digit compounder. Growth is accelerating — latest year outpaced the prior year's rate.
Profit is growing faster than revenue (31% vs 20%) — margin expansion is at work. The latest year saw a +40% swing — check if it's a one-off or structural.
Operating margin has expanded from 18% to 24% — the business is keeping more of each rupee earned.
ROE at 19% — a respectable return on shareholder capital. Low variance across years — a predictable business that earns steadily on its equity base.
31% EPS CAGR — this is the rate at which each share's claim on earnings is compounding.
Operating cash flow has been positive every year — the business generates real cash, not just accounting profit. Investing outflows exceed operating cash — the company relies on external funding to finance expansion. Raising capital despite positive cash flow — could signal expansion plans or opportunistic fundraising.
When operating cash keeps pace with reported profit, earnings are cash-backed; a persistent shortfall is a quality flag.
Revenue fell 18% QoQ — could be seasonality or a genuine slowdown. Wide quarterly swings (43% spread) — likely seasonality, lumpy orders, or project-based revenue. Run-rate stepping up — recent quarters average 49% above earlier ones.
Profit fell 31% QoQ — one-quarter drops can be noise, but a pattern matters. Quarterly net margins are expanding (19% → 23%) — profitability per rupee of revenue is improving.
How today's P/E compares to the stock's own historical range. Dashed line = the 3.6y median.
Promoters at 32.3% — dispersed ownership; institutional flows drive the stock. MF holding up 2.1pp — domestic institutional discovery underway.
Produced by a rules-based engine over licensed exchange fundamentals — every sentence above is derived from the numbers shown, no analyst or AI opinion involved. Education and research context, not investment advice. We are not SEBI-registered as an Investment Adviser or Research Analyst.